Antithrombotic Therapy in Arterial Thrombosis and Thromboembolism in COVID-19 : An American College of Chest Physicians Expert Panel Report
Copyright © 2023 American College of Chest Physicians. Published by Elsevier Inc. All rights reserved..
BACKGROUND: Evidence increasingly shows that the risk of thrombotic complications in COVID-19 is associated with a hypercoagulable state. Several organizations have released guidelines for the management of COVID-19-related coagulopathy and prevention of VTE. However, an urgent need exists for practical guidance on the management of arterial thrombosis and thromboembolism in this setting.
RESEARCH QUESTION: What is the current available evidence informing the prevention and management of arterial thrombosis and thromboembolism in patients with COVID-19?.
STUDY DESIGN AND METHODS: A group of approved panelists developed key clinical questions by using the Population, Intervention, Comparator, and Outcome (PICO) format that address urgent clinical questions regarding prevention and management of arterial thrombosis and thromboembolism in patients with COVID-19. Using MEDLINE via PubMed, a literature search was conducted and references were screened for inclusion. Data from included studies were summarized and reviewed by the panel. Consensus for the direction and strength of recommendations was achieved using a modified Delphi survey.
RESULTS: The review and analysis of the literature based on 11 PICO questions resulted in 11 recommendations. Overall, a low quality of evidence specific to the population with COVID-19 was found. Consequently, many of the recommendations were based on indirect evidence and prior guidelines in similar populations without COVID-19.
INTERPRETATION: The existing evidence and panel consensus do not suggest a major departure from the management of arterial thrombosis according to recommendations predating the COVID-19 pandemic. Data on the optimal strategies for prevention and management of arterial thrombosis and thromboembolism in patients with COVID-19 are sparse. More high-quality evidence is needed to inform management strategies in these patients.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:164 |
|---|---|
| Enthalten in: |
Chest - 164(2023), 6 vom: 15. Dez., Seite 1531-1550 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Potpara, Tatjana [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
ACS/PCI |
|---|
| Anmerkungen: |
Date Completed 21.12.2023 Date Revised 02.02.2024 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1016/j.chest.2023.06.032 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM358941946 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM358941946 | ||
| 003 | DE-627 | ||
| 005 | 20240203231843.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.chest.2023.06.032 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1279.xml |
| 035 | |a (DE-627)NLM358941946 | ||
| 035 | |a (NLM)37392958 | ||
| 035 | |a (PII)S0012-3692(23)00938-8 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Potpara, Tatjana |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Antithrombotic Therapy in Arterial Thrombosis and Thromboembolism in COVID-19 |b An American College of Chest Physicians Expert Panel Report |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 21.12.2023 | ||
| 500 | |a Date Revised 02.02.2024 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright © 2023 American College of Chest Physicians. Published by Elsevier Inc. All rights reserved. | ||
| 520 | |a BACKGROUND: Evidence increasingly shows that the risk of thrombotic complications in COVID-19 is associated with a hypercoagulable state. Several organizations have released guidelines for the management of COVID-19-related coagulopathy and prevention of VTE. However, an urgent need exists for practical guidance on the management of arterial thrombosis and thromboembolism in this setting | ||
| 520 | |a RESEARCH QUESTION: What is the current available evidence informing the prevention and management of arterial thrombosis and thromboembolism in patients with COVID-19? | ||
| 520 | |a STUDY DESIGN AND METHODS: A group of approved panelists developed key clinical questions by using the Population, Intervention, Comparator, and Outcome (PICO) format that address urgent clinical questions regarding prevention and management of arterial thrombosis and thromboembolism in patients with COVID-19. Using MEDLINE via PubMed, a literature search was conducted and references were screened for inclusion. Data from included studies were summarized and reviewed by the panel. Consensus for the direction and strength of recommendations was achieved using a modified Delphi survey | ||
| 520 | |a RESULTS: The review and analysis of the literature based on 11 PICO questions resulted in 11 recommendations. Overall, a low quality of evidence specific to the population with COVID-19 was found. Consequently, many of the recommendations were based on indirect evidence and prior guidelines in similar populations without COVID-19 | ||
| 520 | |a INTERPRETATION: The existing evidence and panel consensus do not suggest a major departure from the management of arterial thrombosis according to recommendations predating the COVID-19 pandemic. Data on the optimal strategies for prevention and management of arterial thrombosis and thromboembolism in patients with COVID-19 are sparse. More high-quality evidence is needed to inform management strategies in these patients | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Practice Guideline | |
| 650 | 4 | |a Research Support, Non-U.S. Gov't | |
| 650 | 4 | |a ACS/PCI | |
| 650 | 4 | |a COVID-19 | |
| 650 | 4 | |a PAD | |
| 650 | 4 | |a atrial fibrillation | |
| 650 | 4 | |a limb ischemia | |
| 650 | 4 | |a stent thrombosis | |
| 650 | 4 | |a stroke | |
| 650 | 7 | |a Anticoagulants |2 NLM | |
| 650 | 7 | |a Fibrinolytic Agents |2 NLM | |
| 700 | 1 | |a Angiolillo, Dominick J |e verfasserin |4 aut | |
| 700 | 1 | |a Bikdeli, Behnood |e verfasserin |4 aut | |
| 700 | 1 | |a Capodanno, Davide |e verfasserin |4 aut | |
| 700 | 1 | |a Cole, Oana |e verfasserin |4 aut | |
| 700 | 1 | |a Yataco, Angel Coz |e verfasserin |4 aut | |
| 700 | 1 | |a Dan, Gheorghe-Andrei |e verfasserin |4 aut | |
| 700 | 1 | |a Harrison, Stephanie |e verfasserin |4 aut | |
| 700 | 1 | |a Iaccarino, Jonathan M |e verfasserin |4 aut | |
| 700 | 1 | |a Moores, Lisa K |e verfasserin |4 aut | |
| 700 | 1 | |a Ntaios, George |e verfasserin |4 aut | |
| 700 | 1 | |a Lip, Gregory Y H |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Chest |d 1970 |g 164(2023), 6 vom: 15. Dez., Seite 1531-1550 |w (DE-627)NLM000002720 |x 1931-3543 |7 nnns |
| 773 | 1 | 8 | |g volume:164 |g year:2023 |g number:6 |g day:15 |g month:12 |g pages:1531-1550 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.chest.2023.06.032 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 164 |j 2023 |e 6 |b 15 |c 12 |h 1531-1550 | ||